Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
8ZRrJAtwt8EX4GuY
